All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @a.genz.mum on TikTok · 18s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @a.genz.mum's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00I'll put the portra break up down, get this biffy hat into blow, it makes a round sound
  2. 0:11On my lap, push it back and go to town, now I'm putting rap on my back and I'm black and
  3. 0:16slacking clown

Can you lose weight while breastfeeding instead of Ozempic?

a.genz.mum

TikTok creator

160.9K viewsWatch on TikTok

Quick answer

The caption describes a postpartum breastfeeding individual who declined semaglutide (Ozempic) on clinical advice due to lactation contraindications and instead achieved 17kg of weight loss through undisclosed behavioral interventions. The spoken transcript is unintelligible and contributes no verifiable clinical claims. Current FDA and EMA guidance contraindicates semaglutide during breastfeeding due to absence of human safety data and animal evidence of milk transfer.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Can you lose weight while breastfeeding instead of Ozempic?, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "Can you lose weight while breastfeeding instead of Ozempic?" from a.genz.mum. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The caption describes a postpartum breastfeeding individual who declined semaglutide (Ozempic) on clinical advice due to lactation contraindications and instead achieved 17kg of weight loss through undisclosed behavioral interventions.

The reason this review is not generic is the source wording and the canonical claim label "glp1 90 days left in 2025 we ve got this as a breastfeeding." In this clip, the useful excerpt is: "I'll put the portra break up down, get this biffy hat into blow, it makes a round sound On my lap, push it back and go to town, now I'm putting rap on my back and I'm black and slacking clown" That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Breastfeeding burns approximately 300 to 500 additional calories per day, contributing to postpartum energy deficit when combined with dietary change (Neville et al.
People who land here are usually comparing the Compounded Semaglutide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Semaglutide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The caption describes a postpartum breastfeeding individual who declined semaglutide (Ozempic) on clinical advice due to lactation contraindications and instead achieved 17kg of weight loss through undisclosed behavioral interventions.

FormBlends verdict

Compounded Semaglutide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The caption describes a postpartum breastfeeding individual who declined semaglutide (Ozempic) on clinical advice due to lactation contraindications and instead achieved 17kg of weight loss through undisclosed behavioral interventions. The spoken transcript is unintelligible and contributes no verifiable clinical claims. Current FDA and EMA guidance contraindicates semaglutide during breastfeeding due to absence of human safety data and animal evidence of milk transfer.
  • The FDA, EMA, and LactMed all contraindicate semaglutide during breastfeeding due to zero human safety data and evidence of animal milk transfer.
  • Breastfeeding burns approximately 300 to 500 additional calories per day, contributing to postpartum energy deficit when combined with dietary change (Neville et al., 2011, American Journal of Clinical Nutrition).

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • The FDA, EMA, and LactMed all contraindicate semaglutide during breastfeeding due to zero human safety data and evidence of animal milk transfer.
  • Breastfeeding burns approximately 300 to 500 additional calories per day, contributing to postpartum energy deficit when combined with dietary change (Neville et al., 2011, American Journal of Clinical Nutrition).
  • A 2022 systematic review in Obesity Reviews found most postpartum weight retention resolves within 12 to 18 months with behavioral support, making medication-free loss plausible but not universal.
  • The creator's spoken transcript is unintelligible, so all fact-checking is based on the written caption only. No spoken medical claims could be evaluated.
  • Semaglutide has a half-life of approximately one week and crosses biological membranes. Its effects on a breastfed infant's GLP-1 receptors are entirely unknown.
  • Postpartum weight loss outcomes depend heavily on sleep, mental health, metabolic history, and socioeconomic access to food and exercise, not discipline alone.
  • Anyone past the breastfeeding period considering GLP-1 therapy for postpartum weight management should consult a licensed provider, not base decisions on social media results.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @a.genz.mum actually say?

The creator's transcript is, frankly, incoherent. The audio appears garbled or corrupted beyond any meaningful interpretation. What we can work with is the caption, where she claims she was told to stop breastfeeding to start Ozempic, refused, and lost 17kg anyway. That caption claim is specific enough to fact-check, even if the spoken words give us nothing usable.

Her core assertion is straightforward: a clinician advised her that GLP-1 receptor agonist therapy (specifically semaglutide, sold as Ozempic) was incompatible with breastfeeding, and she chose to forgo the medication and still achieved significant postpartum weight loss. She frames this as a personal challenge rather than a universal prescription. That framing matters, and we should give her credit for it.

Does the science back this up?

On the breastfeeding-plus-semaglutide question, the clinical guidance is genuinely restrictive, and her doctor was not wrong. The evidence base here is thin but consistently cautious.

Semaglutide has not been studied in breastfeeding humans. Animal studies show it transfers into milk, and given its mechanism as a GLP-1 receptor agonist that suppresses appetite and slows gastric emptying, there is legitimate concern about infant exposure affecting growth and feeding behavior. The European Medicines Agency and the FDA both list breastfeeding as a contraindication for semaglutide products including Ozempic and Wegovy. The Drugs and Lactation Database (LactMed), maintained by the National Institutes of Health, states there is no published data on semaglutide use during lactation and recommends avoiding it.

So the advice she received, stop breastfeeding before starting Ozempic, reflects current clinical consensus. It is not overcaution. It is the guideline.

What did they get wrong (or right)?

She got the core safety framing right without probably realizing it. Declining semaglutide while breastfeeding is the medically appropriate choice given current evidence. The 17kg weight loss claim is unverifiable from this video, but postpartum weight loss of that magnitude over a meaningful period is biologically plausible through dietary change, increased activity, and the caloric demands of lactation itself.

Breastfeeding does burn roughly 300 to 500 additional calories per day, which is not trivial. A 2011 study by Neville et al. in the American Journal of Clinical Nutrition found that while breastfeeding alone does not guarantee weight loss, it contributes to energy deficit when combined with behavioral changes. Her result is consistent with that literature.

What she gets wrong, or at least incomplete, is implying that her path is replicable or equally accessible for everyone. Postpartum weight loss is affected by sleep deprivation, mental health status, socioeconomic factors, and pre-pregnancy metabolic health. Framing 17kg of loss as a personal discipline win, without acknowledging those variables, is misleading even when unintentionally so.

What should you actually know?

If you are breastfeeding and considering GLP-1 medications, the current answer from every major regulatory body is: wait. This is not a conspiracy between pharma and ob-gyns. It is a genuine data gap with a precautionary response.

The absence of evidence is not evidence of safety, particularly when the pharmacology gives plausible reasons for concern. Semaglutide has a half-life of approximately one week, it crosses biological membranes, and its effects on a developing infant's GLP-1 receptors are entirely unknown.

Postpartum weight loss without medication is achievable for many people, but the timeline and magnitude vary enormously. A 2022 systematic review by Gunderson et al. in Obesity Reviews found that most postpartum weight retention resolves within 12 to 18 months in people with access to behavioral support. The creator's result is real for her. It is not a benchmark.

If you are past the breastfeeding period and considering semaglutide or tirzepatide for postpartum weight management, that is a conversation worth having with a licensed provider who can assess your full clinical picture, not a TikTok comment section.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

a.genz.mum · TikTok creator

160.9K views on this video

✨ 90 days left in 2025! We’ve got this! As a breastfeeding mum, I was told I needed to stop in order to start Ozempic but I’m proud to say I lost 17kg without 💪 No shame at all to anyone who choose

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about the fda, ema,?

The FDA, EMA, and LactMed all contraindicate semaglutide during breastfeeding due to zero human safety data and evidence of animal milk transfer.

What does the video say about breastfeeding burns approximately 300 to 500 additional calories per day,?

Breastfeeding burns approximately 300 to 500 additional calories per day, contributing to postpartum energy deficit when combined with dietary change (Neville et al., 2011, American Journal of Clinical Nutrition).

What does the video say about a 2022 systematic review in obesity reviews found most postpartum?

A 2022 systematic review in Obesity Reviews found most postpartum weight retention resolves within 12 to 18 months with behavioral support, making medication-free loss plausible but not universal.

What does the video say about the creator's spoken transcript?

The creator's spoken transcript is unintelligible, so all fact-checking is based on the written caption only. No spoken medical claims could be evaluated.

What does the video say about semaglutide has a half-life of approximately one week?

Semaglutide has a half-life of approximately one week and crosses biological membranes. Its effects on a breastfed infant's GLP-1 receptors are entirely unknown.

What does the video say about postpartum weight loss outcomes depend heavily on sleep, mental health,?

Postpartum weight loss outcomes depend heavily on sleep, mental health, metabolic history, and socioeconomic access to food and exercise, not discipline alone.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by a.genz.mum, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.